Literature DB >> 11476839

Linezolid resistance in a clinical isolate of Staphylococcus aureus.

S Tsiodras, H S Gold, G Sakoulas, G M Eliopoulos, C Wennersten, L Venkataraman, R C Moellering, M J Ferraro.   

Abstract

The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476839     DOI: 10.1016/S0140-6736(01)05410-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  206 in total

1.  Effect of linezolid in comparison with that of vancomycin on glycocalix production: in vitro study.

Authors:  L Drago; E De Vecchi; M Valli; L Nicola; M R Gismondo
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis.

Authors:  Neil Woodford; Luke Tysall; Cressida Auckland; Mark W Stockdale; Andrew J Lawson; Rachel A Walker; David M Livermore
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci.

Authors:  Alistair Sinclair; Catherine Arnold; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

4.  Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae.

Authors:  Sue E Baum; Sharon A Crawford; M L McElmeel; Cynthia G Whitney; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 5.  Antimicrobial resistance: the example of Staphylococcus aureus.

Authors:  Franklin D Lowy
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

6.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

7.  Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.

Authors:  S H Marshall; C J Donskey; R Hutton-Thomas; R A Salata; L B Rice
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

9.  In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.

Authors:  Ji-Woong Jeong; Sung-Ji Jung; Hyun-Hee Lee; Yong-Zu Kim; Tae-Kyo Park; Young-Lag Cho; Sang-Eun Chae; Sung-Yoon Baek; Sung-Ho Woo; Hyang-Sook Lee; Jin-Hwan Kwak
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

10.  Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate.

Authors:  Anna C Shore; Orla M Brennan; Ralf Ehricht; Stefan Monecke; Stefan Schwarz; Peter Slickers; David C Coleman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.